Zacks: Analysts Anticipate Xeris Pharmaceuticals Inc (NASDAQ:XERS) Will Announce Earnings of -$1.21 Per Share

Wall Street brokerages expect that Xeris Pharmaceuticals Inc (NASDAQ:XERS) will report earnings of ($1.21) per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Xeris Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($1.17) and the lowest estimate coming in at ($1.24). Xeris Pharmaceuticals reported earnings of ($0.98) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 23.5%. The company is expected to report its next quarterly earnings results on Wednesday, March 4th.

According to Zacks, analysts expect that Xeris Pharmaceuticals will report full-year earnings of ($4.79) per share for the current year, with EPS estimates ranging from ($4.84) to ($4.73). For the next financial year, analysts anticipate that the company will post earnings of ($3.37) per share, with EPS estimates ranging from ($3.68) to ($3.06). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Xeris Pharmaceuticals.

Xeris Pharmaceuticals (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.22) EPS for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.01. The firm had revenue of $0.32 million during the quarter, compared to analysts’ expectations of $0.20 million. Xeris Pharmaceuticals had a negative return on equity of 150.08% and a negative net margin of 6,697.33%.

A number of analysts recently commented on the company. Mizuho reiterated a “buy” rating and set a $22.00 price objective on shares of Xeris Pharmaceuticals in a research report on Thursday, November 21st. Royal Bank of Canada set a $18.00 price objective on Xeris Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 7th. ValuEngine cut Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, September 30th. Finally, Zacks Investment Research upgraded Xeris Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 16th.

In other Xeris Pharmaceuticals news, insider Paul R. Edick purchased 17,935 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were purchased at an average cost of $8.55 per share, with a total value of $153,344.25. Following the purchase, the insider now owns 172,935 shares in the company, valued at $1,478,594.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Steven Prestrelski sold 27,700 shares of the firm’s stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $9.00, for a total value of $249,300.00. Company insiders own 7.43% of the company’s stock.

A number of large investors have recently modified their holdings of XERS. Bank of Montreal Can acquired a new stake in Xeris Pharmaceuticals in the 2nd quarter worth about $26,000. Tower Research Capital LLC TRC acquired a new stake in Xeris Pharmaceuticals in the 2nd quarter worth about $42,000. Marshall Wace North America L.P. acquired a new stake in Xeris Pharmaceuticals in the 1st quarter worth about $71,000. Metropolitan Life Insurance Co NY acquired a new stake in Xeris Pharmaceuticals in the 3rd quarter worth about $100,000. Finally, Susquehanna International Group LLP acquired a new stake in Xeris Pharmaceuticals in the 2nd quarter worth about $118,000. 66.37% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Pharmaceuticals stock traded up $0.14 during midday trading on Wednesday, reaching $8.94. 125,806 shares of the company were exchanged, compared to its average volume of 196,196. The company has a market capitalization of $241.07 million, a price-to-earnings ratio of -1.79 and a beta of -0.39. The firm’s 50-day simple moving average is $8.34 and its 200-day simple moving average is $10.21. Xeris Pharmaceuticals has a 1 year low of $6.85 and a 1 year high of $20.90. The company has a debt-to-equity ratio of 1.33, a quick ratio of 5.96 and a current ratio of 5.96.

Xeris Pharmaceuticals Company Profile

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

Read More: Profit margin is different from the revenue

Get a free copy of the Zacks research report on Xeris Pharmaceuticals (XERS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xeris Pharmaceuticals (NASDAQ:XERS)

Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.